Autonomous Aldosterone Secretion as a Subclinical Form of Primary Aldosteronism: Pathogenesis and Clinical Significance

Abstract

In recent years, a substantial prevalence of primary aldosteronism (PA) has been demonstrated in both normotensive and mildly hypertensive cohorts. Consequently, a classic presentation of the syndrome, i. e. moderate-to-severe and resistant hypertension with concomitant hypokalemia, should be considered a tip-of-the-iceberg phenotype of a wide PA spectrum. Its entire range encompasses the non-classic clinical forms of mild hypertension and prehypertension but also several biochemical presentations, including patients who meet PA screening and confirmation test criteria, as well as those with either of them and those with other parameters indicating mineralocorticoid excess. In the current review, research insights on the pathogenetic background and clinical significance of autonomous aldosterone secretion (AAS) are presented, which is defined as a constellation of either: 1) normotension, normokalemia, a positive PA screening (high aldosterone-to-renin ratio) and/or confirmation test, or 2) hypertension, normokalemia and a positive PA screening but negative confirmation test. For this purpose, a literature search of the PubMed database was conducted. Advances in immunohistochemistry and genetic sequencing of isolated adrenal cells are provided as probable morphologic basis of the wide range of aldosterone secretion autonomy. Also, the role of corticotropin as an aldosterone secretagogue is discussed. To date, clinical studies depict consequences of subclinical PA phenotypes, such as increased mortality and risk of developing hypertension, impaired arterial and kidney function, association with metabolic syndrome and age, as well as osteoporosis.

Key words

hyperaldosteronism etiology - aldosterone - renin - hypertension - adrenal glands physiopathology - hyperaldosteronism diagnosis

Publication History

Received: 07 January 2021
Received: 03 June 2021

Accepted: 19 July 2021

Article published online:
06 October 2021

• References

• 1 Conn JW. Part I. Painting background. Part II. Primary aldosteronism, a new clinical syndrome, 1954. J Lab Clin Med 1990; 116: 253-267
• 2 Litynski M. Hypertension caused by tumors of the adrenal cortex. Pol Tyg Lek 1953; 8: 204-208
• 3 Vaidya A, Carey RM. Evolution of the primary aldosteronism syndrome: updating the approach. J Clin Endocrinol Metab 2020; 105: dgaa606
• 4 Funder JW, Carey RM, Mantero F. et al. The Management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016; 101: 1889-1916
• 5 Mulatero P, Monticone S, Deinum J. et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension *. J Hypertens 2020; 38: 1919-1928
• 6 Schilbach K, Junnila RK, Bidlingmaier M. Aldosterone to renin ratio as screening tool in primary aldosteronism. Exp Clin Endocrinol Diabetes 2019; 127: 84-92
• 7 O’Shea JPM, Griffin TP, Denieffe S. et al. The aldosterone to renin ratio in the diagnosis of primary aldosteronism: Promises and challenges. Int J Clin Pract 2019; 73
• 8 Leung AA, Orton DJ, Chin A. et al. Novel approach to establishing an aldosterone: renin ratio cutoff for primary aldosteronism. Hypertension 2017; 69: 450-456
• 9 Ahmed AH, Cowley D, Wolley M. et al. Seated saline suppression testing for the diagnosis of primary aldosteronism: a preliminary study. J Clin Endocrinol Metab 2014; 99: 2745-2753
• 10 Vaidya A, Mulatero P, Baudrand R. et al. The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment. Endocr Rev 2018; 39: 1057-1088
• 11 Rossi GP. Primary aldosteronism: JACC state-of-the-art review. J Am Coll Cardiol 2019; 74: 2799-2811
• 12 Nishikawa T, Omura M. Should primary aldosteronism be diagnosed among normotensive subjects during general health check-up and/or at general outpatient clinics?. Hypertens Res 2011; 34: 47-48
• 13 Nishikawa T, Omura M, Satoh F. et al. Guidelines for the diagnosis and treatment of primary aldosteronism–the Japan Endocrine Society 2009. Endocr J 2011; 58: 711-721
• 14 Monticone S, Burrello J, Tizzani D. et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol 2017; 69: 1811-1820
• 15 Brown JM, Siddiqui M, Calhoun DA. et al. The unrecognized prevalence of primary aldosteronism: a cross-sectional study. Ann Intern Med 2020; 173: 10-20
• 16 Baudrand R, Guarda FJ, Fardella C. et al. Continuum of renin-independent aldosteronism in normotension. Hypertens Dallas Tex 1979 2017; 69: 950-956
• 17 Markou A, Pappa T, Kaltsas G. et al. Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: a very high odds ratio for progression into arterial hypertension. J Clin Endocrinol Metab 2013; 98: 1409-1416
• 18 Piaditis GP, Kaltsas G, Markou A. et al. Five reasons for the failure to diagnose aldosterone excess in hypertension. Horm Metab Res 2020; a-1236-a-4869
• 19 Maiolino G, Rossitto G, Bisogni V. et al. Quantitative value of aldosterone-renin ratio for detection of aldosterone-producing adenoma: the aldosterone-renin ratio for primary aldosteronism (AQUARR) Study. J Am Heart Assoc 2017; 6
• 20 Papanastasiou L, Markou A, Pappa T. et al. Primary aldosteronism in hypertensive patients: clinical implications and target therapy. Eur J Clin Invest 2014; 44: 697-706
• 21 Gouli A, Kaltsas G, Tzonou A. et al. High prevalence of autonomous aldosterone secretion among patients with essential hypertension. Eur J Clin Invest 2011; 41: 1227-1236
• 22 Piaditis GP, Kaltsas GA, Androulakis II. et al. High prevalence of autonomous cortisol and aldosterone secretion from adrenal adenomas. Clin Endocrinol (Oxf) 2009; 71: 772-778
• 23 Pappa T, Papanastasiou L, Kaltsas G. et al. Pattern of adrenal hormonal secretion in patients with adrenal adenomas: the relevance of aldosterone in arterial hypertension. J Clin Endocrinol Metab 2012; 97: E537-E545
• 24 Buffolo F, Monticone S, Pecori A. et al. The spectrum of low-renin hypertension. Best Pract Res Clin Endocrinol Metab 2020; 101399
• 25 Ito Y, Takeda R, Takeda Y. Subclinical primary aldosteronism. Best Pract Res Clin Endocrinol Metab 2012; 26: 485-495
• 26 Cao CX, Yang XC, Gao YX. et al. Expression of aldosterone synthase and adrenocorticotropic hormone receptor in adrenal incidentalomas from normotensive and hypertensive patients: Distinguishing subclinical or atypical primary aldosteronism from adrenal incidentaloma. Int J Mol Med 2012; 30: 1396-1402
• 27 Chen Y-C, Su Y-C, Wei C-K. et al. Diagnostic value of I-131 NP-59 SPECT/CT scintigraphy in patients with subclinical or atypical features of primary aldosteronism. J Biomed Biotechnol 2011; 2011: 209787
• 28 Luo Q, Li N, Wang M. et al. Mild primary aldosteronism (PA) followed by overt PA are possibly the most common forms of low renin hypertension: a single-center retrospective study. J Hum Hypertens 2019;
• 29 Karashima S, Kometani M, Tsujiguchi H. et al. Prevalence of primary aldosteronism without hypertension in the general population: Results in Shika study. Clin Exp Hypertens N Y N 1993 2018; 40: 118-125
• 30 Médeau V, Moreau F, Trinquart L. et al. Clinical and biochemical characteristics of normotensive patients with primary aldosteronism: a comparison with hypertensive cases. Clin Endocrinol (Oxf) 2008; 69: 20-28
• 31 Lin X, Miao X, Zhu P. et al. A normotensive patient with primary aldosteronism. Case Rep Endocrinol 2017; 2017: 5159382
• 32 Tang A, Pasieka J, Kline G. Normotensive hypokalemic primary aldosteronism: how is this Possible?. Endocr Abstr 2018;
• 33 Ito Y, Takeda R, Karashima S. et al. Prevalence of primary aldosteronism among prehypertensive and stage 1 hypertensive subjects. Hypertens Res Off J Jpn Soc Hypertens 2011; 34: 98-102
• 34 Brown JM, Robinson-Cohen C, Luque-Fernandez MA. et al. The spectrum of subclinical primary aldosteronism and incident hypertension: a cohort study. Ann Intern Med 2017; 167: 630-641
• 35 Chiodini I, Albani A, Ambrogio AG. et al. Six controversial issues on subclinical Cushing’s syndrome. Endocrine 2017; 56: 262-266
• 36 Biondi B, Cooper DS. Subclinical hyperthyroidism. N Engl J Med 2018; 378: 2411-2419
• 37 Willenberg H, Schinner S, Ansurudeen I. New mechanisms to control aldosterone synthesis. Horm Metab Res 2008; 40: 435-441
• 38 Lacroix A, Bourdeau I, Lampron A. et al. Aberrant G-protein coupled receptor expression in relation to adrenocortical overfunction. Clin Endocrinol (Oxf) 2009;
• 39 Gomez-Sanchez CE, Qi X, Velarde-Miranda C. et al. Development of monoclonal antibodies against human CYP11B1 and CYP11B2. Mol Cell Endocrinol 2014; 383: 111-117
• 40 Nakamura Y, Maekawa T, Felizola SJA. et al. Adrenal CYP11B1/2 expression in primary aldosteronism: Immunohistochemical analysis using novel monoclonal antibodies. Mol Cell Endocrinol 2014; 392: 73-79
• 41 Omata K, Anand SK, Hovelson DH. et al. Aldosterone-producing cell clusters frequently harbor somatic mutations and accumulate with age in normal adrenals. J Endocr Soc 2017; 1: 787-799
• 42 Nanba K, Vaidya A, Williams GH. et al. Age-related autonomous aldosteronism. Circulation 2017; 136: 347-355
• 43 Nishimoto K, Tomlins SA, Kuick R. et al. Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands. Proc Natl Acad Sci USA 2015; 112: E4591-E4599
• 44 Williams TA, Gomez-Sanchez CE, Rainey WE. et al. International histopathology consensus for unilateral primary aldosteronism. J Clin Endocrinol Metab 2021; 106: 42-54
• 45 Lalli E, Barhanin J, Zennaro M-C. et al. Local control of aldosterone production and primary aldosteronism. Trends Endocrinol Metab TEM 2016; 27: 123-131
• 46 Omata K, Satoh F, Morimoto R. et al. Cellular and genetic causes of idiopathic hyperaldosteronism. Hypertens Dallas Tex 1979 2018; 72: 874-880
• 47 Nishimoto K, Koga M, Seki T. et al. Immunohistochemistry of aldosterone synthase leads the way to the pathogenesis of primary aldosteronism. Mol Cell Endocrinol 2017; 441: 124-133
• 48 Yamazaki Y, Nakamura Y, Omata K. et al. Histopathological classification of cross-sectional image negative hyperaldosteronism. J Clin Endocrinol Metab 2016; jc.2016-2986
• 49 Azizan EAB, Poulsen H, Tuluc P. et al. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet 2013; 45: 1055-1060
• 50 Rossi GP. Does primary aldosteronism exist in normotensive and mildly hypertensive patients, and should we look for it?. Hypertens Res 2011; 34: 43-46
• 51 Kem DC, Weinberger MH, Gomez-Sanchez C. et al. The role of ACTH in the episodic release of aldosterone in patients with idiopathic adrenal hyperplasia, hypertension, and hyperaldosteronism. J Lab Clin Med 1976; 88: 261-270
• 52 Fardella CE, Mosso L, Gómez-Sánchez C. et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000; 85: 1863-1867
• 53 Martin Martins J, do Vale S, Martins AF. Mild adrenal steroidogenic defects and ACTH-dependent aldosterone secretion in high blood pressure: preliminary evidence. Int J Endocrinol 2014; 2014: 1-8
• 54 Markou A, Sertedaki A, Kaltsas G. et al. Stress-induced aldosterone hyper-secretion in a substantial subset of patients with essential hypertension. J Clin Endocrinol Metab 2015; 100: 2857-2864
• 55 Vasan RS, Evans JC, Larson MG. et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351: 33-41
• 56 Newton-Cheh C, Guo C-Y, Gona P. et al. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertens 2007; 49: 846-856
• 57 Inoue K, Goldwater D, Allison M. et al. Serum aldosterone concentration, blood pressure, and coronary artery calcium: the multi-ethnic study of atherosclerosis. Hypertens 2020; 76: 113-120
• 58 Hundemer GL, Baudrand R, Brown JM. et al. Renin phenotypes characterize vascular disease, autonomous aldosteronism, and mineralocorticoid receptor activity. J Clin Endocrinol Metab 2017; 102: 1835-1843
• 59 Brown JM, Underwood PC, Ferri C. et al. Aldosterone dysregulation with aging predicts renal vascular function and cardiovascular risk. Hypertens 2014; 63: 1205-1211
• 60 Vaidya A, Underwood PC, Hopkins PN. et al. Abnormal aldosterone physiology and cardiometabolic risk factors. Hypertens 2013; 61: 886-893
• 61 Vecchiola A, Fuentes CA, Barros ER. et al. The aldosterone/renin ratio predicts cardiometabolic disorders in subjects without classic primary aldosteronism. Am J Hypertens 2019; 32: 468-475
• 62 Kokko E, Nevalainen PI, Choudhary MK. et al. Aldosterone-to-renin ratio is related to arterial stiffness when the screening criteria of primary aldosteronism are not met. Sci Rep 2020; 10: 19804
• 63 Duffy SJ, Biegelsen ES, Eberhardt RT. et al. Low-renin hypertension with relative aldosterone excess is associated with impaired NO-mediated vasodilation. Hypertens 2005; 46: 707-713
• 64 Hannemann A, Wallaschofski H, Lüdemann J. et al. Plasma aldosterone levels and aldosterone-to-renin ratios are associated with endothelial dysfunction in young to middle-aged subjects. Atherosclerosis 2011; 219: 875-879
• 65 Shu X, Mei M, Ma L. et al. Postmenopausal osteoporosis is associated with elevated aldosterone/renin ratio. J Hum Hypertens 2018; 32: 524-530
• 66 Murata M, Kitamura T, Tamada D. et al. Plasma aldosterone level within the normal range is less associated with cardiovascular and cerebrovascular risk in primary aldosteronism. J Hypertens 2017; 35: 1079-1085
• 67 Williams B, MacDonald TM, Morant S. et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet Lond Engl 2015; 386: 2059-2068